HomeCompareRPTX vs BTI

RPTX vs BTI: Dividend Comparison 2026

RPTX yields 75.47% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPTX wins by $1.32M in total portfolio value
10 years
RPTX
RPTX
● Live price
75.47%
Share price
$2.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.35M
Annual income
$375,142.22
Full RPTX calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — RPTX vs BTI

📍 RPTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPTXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPTX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPTX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPTX
Annual income on $10K today (after 15% tax)
$6,415.09/yr
After 10yr DRIP, annual income (after tax)
$318,870.89/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, RPTX beats the other by $316,502.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPTX + BTI for your $10,000?

RPTX: 50%BTI: 50%
100% BTI50/50100% RPTX
Portfolio after 10yr
$695.3K
Annual income
$188,964.43/yr
Blended yield
27.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

RPTX
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Price Target
$3.00
+13.2% upside vs current
Range: $3.00 — $3.00
Altman Z
-0.1
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPTX buys
0
BTI buys
0
No recent congressional trades found for RPTX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPTXBTI
Forward yield75.47%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$1.35M$37.7K
Annual income after 10y$375,142.22$2,786.64
Total dividends collected$1.17M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$3.00$40.00

Year-by-year: RPTX vs BTI ($10,000, DRIP)

YearRPTX PortfolioRPTX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$18,247$7,547.17$11,299$598.92+$6.9KRPTX
2$32,395$12,870.51$12,794$703.91+$19.6KRPTX
3$56,017$21,354.74$14,518$829.07+$41.5KRPTX
4$94,449$34,510.84$16,513$978.64+$77.9KRPTX
5$155,442$54,381.15$18,827$1,157.84+$136.6KRPTX
6$249,967$83,643.80$21,518$1,373.12+$228.4KRPTX
7$393,173$125,708.24$24,657$1,632.46+$368.5KRPTX
8$605,486$184,791.09$28,329$1,945.74+$577.2KRPTX
9$913,831$265,960.98$32,637$2,325.33+$881.2KRPTX
10$1,352,941$375,142.22$37,708$2,786.64+$1.32MRPTX

RPTX vs BTI: Complete Analysis 2026

RPTXStock

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Full RPTX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this RPTX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPTX vs SCHDRPTX vs JEPIRPTX vs ORPTX vs KORPTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.